GP IIb/IIIa antagonists are potent inhibitors of platelet aggregation. A clear understanding of the bleeding risks associated with their use is of particular importance in the cardiac ...

as well as the autologous reaction (maternal serum tested against maternal platelets), showed negative results for glycoprotein Ia-IIa, IIb-IIIa, and Ib-IX complexes. Similarly, indirect MAIPA ...

The antithrombotic efficacy of the monoclonal antibodies 6B4-Fab and MA-16N7C2 against platelet glycoprotein (GP) Ib and GP IIb/IIIa, respectively, on acute platelet-mediated thrombosis was evaluated ...

Mean age at the first sampling was 43,6 and the second 48,6 years. Antibodies towards platelet glycoproteins (GP) IIb/IIIa, GP V and GP Ib/IX were detected in H and L serum samples, using the direct ...

subsequent platelet activation and thrombus initiation. CD40L - CD40 ligand; SLC44A2 - solute carrier family 44 member 2; GP IIb/IIIa - glycoprotein IIb/IIIa; Mac-1 - macrophage-1 antigen complex; GP ...

Today's approval marks the fifth indication for KEYTRUDA in non-small cell lung cancer and the first indication for KEYTRUDA in patients with resected stage IB (T2a 4 cm), II, or IIIA disease ...

for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer (NSCLC). The approval was ...

The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer-reviewed. Use of glycoprotein IIb/IIIa inhibitors (GPI) was associated with increased ...

Treatment options for stages I and IIA and IIB are surgery and, later ... Adjuvant targeted therapy has the same results as it has at stage IA or IB. At stage IIIA, surgical resection of the tumor and ...

RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, ...

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. This is an ASCO Meeting Abstract from the ...